The global anatomic pathology market size is expected to reach USD 65.54 billion by 2030, according to a new study by Polaris Market Research. The report “Anatomic Pathology Market Share, Size, Trends, Industry Analysis Report, By Product; By Application (Disease Diagnosis, Drug Discovery and Development, Others); By End-Use (Hospitals, Research Laboratories, Diagnostic Laboratories, Others), By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The global industry is expected to increase rapidly due to the growing focus on customized care and a large number of supporting programs and training modules provided by the government. The geriatric population is rapidly growing, as is the incidence rate of cancer and other chronic disorders. The industry is being driven by an increase in chronic disease cases and a need to address the quick diagnosis of medical disorders. Modern anatomic pathology technology is becoming more widely used because of the significant rise in cancer cases.
The industry is being driven by an increase in chronic disease cases and a need to address the quick diagnosis of medical disorders. Because the elderly are more susceptible to numerous illnesses, this demographic trend is expected to significantly increase the prevalence of several chronic diseases, including cancer, worldwide.
Furthermore, rising awareness and increased patient pool in developing countries propel the industry forward. Additionally, the industry is being driven by an increase in healthcare expenditure and the use of biomarkers during illness diagnosis.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/anatomic-pathology-market/request-for-sample
Over the projected period, the drug discovery and development segment is expected to increase at a profitable rate. During preclinical studies, pathologists' tissue analysis provides pharmaceutical companies with a wide range of information. Moreover, the biologic's manufacturing service is also expected to register significant growth in the overall industry. This is due to the robust pipeline of new biological drugs due to the growing commercial success of biopharma companies across developed and developing economies paving the segment's growth.
Agilent Technologies, Abcam plc, Amos Scientific Pty Ltd., Bio SB, BioGenex, Bright Instruments, Cell Signaling Technology, Inc., Beckton, CellPath Ltd., Danaher Corporation, Diapath S.p.A, Dickson and Company, Cardinal Health, F. Hoffmann-La Roche AG, Hologic, Inc., Jinhua Yidi Medical Equipment Co., Ltd., Histo-Line Laboratories, Laboratory Corporation of America Holdings, Lupetec, Medimeas, Merck KGaA, MICROS AUSTRIA, Milestone Medical, NeoGenomics Laboratories, Inc., MEDITE Medical GmbH, Quest Diagnostics Incorporated, R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED, PHC Holdings Corporation, Sakura Finetek, and SLEE medical GmbH are some of the major players in the market.
In December 2021, Quest Diagnostics Incorporated introduced the liquid biopsy-based Target Selector NGS Lung Panel test. In October 2021, Roche partnered with PathAI, a global leader in artificial intelligence (AI)-based technologies. The firms will collaborate on pathologists' embedded image analysis workflow as part of the development and distribution arrangement.
Polaris Market Research has segmented the anatomic pathology market report based on product, application, end-use, and region:
Anatomic Pathology, Product Outlook (Revenue - USD Billion, 2018 - 2030)
Anatomic Pathology, Application Outlook (Revenue - USD Billion, 2018 - 2030)
Anatomic Pathology, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)
Anatomic Pathology, Regional Outlook (Revenue - USD Billion, 2018 - 2030)